Related Experiment Video
Updated: Jun 22, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Trim24 targets endogenous p53 for degradation
Kendra Allton1, Abhinav K Jain, Hans-Martin Herz
1Department of Biochemistry and Molecular Biology, Program in Genes and Development, Graduate School of Biomedical Sciences and Center for Stem Cell and Developmental Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Numerous studies focus on the tumor suppressor p53 as a protector of genomic stability, mediator of cell cycle arrest and apoptosis, and target of mutation in 50% of all human cancers. The vast majority of information on p53, its protein-interaction partners and regulation, comes from studies of tumor-derived, cultured cells where p53 and its regulatory controls may be mutated or dysfunctional. To address regulation of endogenous p53 in normal cells, we created a mouse and stem cell model by knock-in (KI) of a tandem-affinity-purification (TAP) epitope at the endogenous Trp-53 locus. Mass spectrometry of TAP-purified p53-complexes from embryonic stem cells revealed Tripartite-motif protein 24 (Trim24), a previously unknown partner of p53. Mutation of TRIM24 homolog, bonus, in Drosophila led to apoptosis, which could be rescued by p53-depletion. These in vivo analyses establish TRIM24/bonus as a pathway that negatively regulates p53 in Drosophila. The Trim24-p53 link is evolutionarily conserved, as TRIM24 depletion in human breast cancer cells caused p53-dependent, spontaneous apoptosis. We found that Trim24 ubiquitylates and negatively regulates p53 levels, suggesting Trim24 as a therapeutic target to restore tumor suppression by p53.
Insights
Researchers identified Tripartite-motif protein 24 (Trim24) as a novel negative regulator of the tumor suppressor p53. Trim24 targets p53 for ubiquitylation, offering a potential therapeutic strategy for cancer.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- The tumor suppressor p53 is crucial for genomic stability, cell cycle arrest, and apoptosis, but is frequently mutated in human cancers.
- Most p53 research uses cancer cell lines, which may have mutated or dysfunctional p53 regulatory pathways.
- Understanding p53 regulation in normal cells is essential for cancer research.
Purpose of the Study:
- To investigate the regulation of endogenous p53 in normal cells.
- To identify novel p53-interacting proteins and regulatory mechanisms.
- To explore the therapeutic potential of targeting p53 regulators.
Main Methods:
- Created a knock-in mouse and stem cell model with a tandem-affinity-purification (TAP) epitope on endogenous Trp-53.
- Utilized mass spectrometry to identify p53-interacting proteins from purified complexes.
- Performed in vivo studies in Drosophila and human breast cancer cells to validate findings.
Main Results:
- Identified Tripartite-motif protein 24 (Trim24) as a novel p53-binding partner.
- Demonstrated that Trim24 negatively regulates p53 levels through ubiquitylation.
- Showed that Trim24/bonus pathway negatively regulates p53 in Drosophila, and this link is conserved in human cells, where Trim24 depletion causes p53-dependent apoptosis.
Conclusions:
- Trim24 is an evolutionarily conserved negative regulator of p53.
- Trim24-mediated ubiquitylation of p53 impacts tumor suppression.
- Targeting Trim24 may represent a novel therapeutic strategy to restore p53's tumor-suppressive functions.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Negative Regulator Molecules
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability

